Aidoc – the leading provider of AI solutions for radiologists – announced that the FDA has allowed the use of their cleared AI algorithms intended for adjunctive use in the detection of findings associated with COVID-19.
The product detects and prioritizes incidental CT findings associated with COVID-19 (e.g. GGO – a non-specific imaging finding associated with COVID-19 infection) in any CT study that contains the lung or part of the lung – for example chest, abdomen or cervical spine. Prioritization of these incidental findings may help manage the adverse effects of COVID-19 by providing adjunctive information that can promote further patient evaluation.
“In our experience, it is not unusual for the radiologist to be the first to diagnose COVID-19 disease in patients especially when the disease is clinically unsuspected. The outbreak of the COVID-19 pandemic may occur in waves and should these waves occur, it will become increasingly important to identify imaging findings suggestive of COVID-19 in a variety of clinical settings,” said Dr. Paul Chang, Vice-Chair, Radiology Informatics at the University of Chicago Medicine. “Aidoc’s ability to detect and triage patients with incidental findings associated with COVID-19 acts as another layer of protection as the disease may continue to circulate in the months to come.”
In studies published by universities of Brussels, Chicago, and Brescia, as well as a report from Maimonides Medical Center in New York, 8-10% of patients undergoing CT scans for other conditions were discovered by radiologists to have COVID-19. These patients, who were undergoing oncology screenings or being screened for abdominal pain, did not exhibit any COVID-associated respiratory symptoms. Prompt identification of these incidental findings allows the action to be taken sooner with regard to treatment or appropriate isolation.